Literature DB >> 23712799

Antiplatelet therapy, but not intravenous thrombolytic therapy, is associated with postoperative bleeding complications after decompressive craniectomy for stroke.

Patrick Schuss1, Valeri Borger, Hartmut Vatter, Oliver C Singer, Volker Seifert, Erdem Güresir.   

Abstract

Intravenous thrombolysis (IVT) is an established treatment in patients suffering from acute ischemic stroke (AIS). IVT might increase the risk of postoperative complications if applied prior to decompressive craniectomy (DC). Therefore, we analyzed the management of patients with and without IVT prior to DC. Between 1999 and 2011, DC was performed in 115 patients after AIS. Patients with and without IVT prior to DC were compared regarding perioperative management, postoperative complications and outcome. Postoperative complications were stratified into non-bleeding and bleeding complications. Outcome was assessed using the modified Rankin scale after three months. Two multivariate analyses were performed to identify predictors for postoperative complications and predictors for unfavourable outcome (mRS 4-6). Fifty-two of 115 patients underwent IVT prior to DC (45 %). Forty-four patients were on antiplatelet therapy prior to DC (38 %). Frequency of bleeding complications did not differ significantly in patients with IVT prior to DC compared to patients without. However, bleeding complications occurred significantly more often in patients with antiplatelet use prior to DC (p = 0.0003, OR 4.5). In the multivariate analysis "preoperative use of acetylsalicylic acid" was the only independent predictor associated with bleeding complications (p = 0.002, OR 3.9). IVT prior to DC did not predict unfavourable outcome. There was no evidence in this observational study that IVT prior to DC places patients at undue risk of bleeding complications after subsequent DC. Patients with or without IVT prior to DC suffered significantly more often from postoperative bleeding complications if antiplatelet therapy was applied before onset of AIS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23712799     DOI: 10.1007/s00415-013-6950-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  34 in total

1.  Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).

Authors:  V Larrue; R von Kummer R; A Müller; E Bluhmki
Journal:  Stroke       Date:  2001-02       Impact factor: 7.914

2.  Classification and natural history of clinically identifiable subtypes of cerebral infarction.

Authors:  J Bamford; P Sandercock; M Dennis; J Burn; C Warlow
Journal:  Lancet       Date:  1991-06-22       Impact factor: 79.321

3.  Early hemicraniectomy in patients with complete middle cerebral artery infarction.

Authors:  S Schwab; T Steiner; A Aschoff; S Schwarz; H H Steiner; O Jansen; W Hacke
Journal:  Stroke       Date:  1998-09       Impact factor: 7.914

Review 4.  Thrombolytics: drug interactions of clinical significance.

Authors:  S Harder; U Klinkhardt
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

5.  Management of thrombolysis-associated symptomatic intracerebral hemorrhage.

Authors:  Joshua N Goldstein; Marisela Marrero; Shihab Masrur; Muhammad Pervez; Alex M Barrocas; Abdul Abdullah; Alexandra Oleinik; Jonathan Rosand; Eric E Smith; Walter H Dzik; Lee H Schwamm
Journal:  Arch Neurol       Date:  2010-08

6.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

7.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

8.  Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.

Authors: 
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

9.  Decompressive Surgery for the Treatment of Malignant Infarction of the Middle Cerebral Artery (DESTINY): a randomized, controlled trial.

Authors:  Eric Jüttler; Stefan Schwab; Peter Schmiedek; Andreas Unterberg; Michael Hennerici; Johannes Woitzik; Steffen Witte; Ekkehart Jenetzky; Werner Hacke
Journal:  Stroke       Date:  2007-08-09       Impact factor: 7.914

10.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

View more
  4 in total

Review 1.  Complications Associated with Decompressive Craniectomy: A Systematic Review.

Authors:  David B Kurland; Ariana Khaladj-Ghom; Jesse A Stokum; Brianna Carusillo; Jason K Karimy; Volodymyr Gerzanich; Juan Sahuquillo; J Marc Simard
Journal:  Neurocrit Care       Date:  2015-10       Impact factor: 3.210

2.  The Effect of Preoperative Antiplatelet Therapy on Hemorrhagic Complications after Decompressive Craniectomy in Patients with Traumatic Brain Injury.

Authors:  Hokyun Han; Eun Jung Koh; Hyunho Choi; Byong-Cheol Kim; Seung Yeob Yang; Keun-Tae Cho
Journal:  Korean J Neurotrauma       Date:  2016-10-31

Review 3.  Decompressive craniectomy for acute ischemic stroke.

Authors:  Thomas Beez; Christopher Munoz-Bendix; Hans-Jakob Steiger; Kerim Beseoglu
Journal:  Crit Care       Date:  2019-06-07       Impact factor: 9.097

4.  Decompressive Hemicraniectomy in a South American Population--Morbidity and Outcomes Analysis.

Authors:  Roberto Bezerra Vital; Pedro Tadao Hamamoto Filho; Gustavo Jose Luvizutto; Luis Gustavo Ducati; Gabriel Pereira Braga; Helio Rubens de Carvalho Nunes; Flavio Ramalho Romero; Eliana Marisa Ganem; Marco Antonio Zanini; Rodrigo Bazan
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.